Kymera Therapeutics Discusses Phase 1 Study Results

Kymera Therapeutics ( (KYMR) ) has issued an update.

On June 2, 2025, Kymera Therapeutics held a conference call to discuss the results of their Phase 1 study of KT-621, an oral STAT6 degrader for immuno-inflammatory diseases. The study’s findings are part of Kymera’s strategy to disrupt conventional treatment paradigms in immunology, potentially impacting the company’s market positioning and offering new opportunities for stakeholders.

The most recent analyst rating on (KYMR) stock is a Buy with a $46.00 price target. To see the full list of analyst forecasts on Kymera Therapeutics stock, see the KYMR Stock Forecast page.

Spark’s Take on KYMR Stock

According to Spark, TipRanks’ AI Analyst, KYMR is a Neutral.

Kymera’s overall score reflects a blend of strategic advancements and financial challenges. The strong pipeline and financial runway are key strengths, while negative cash flow and technical indicators present risks. Continued innovation and execution will be critical for future performance.

To see Spark’s full report on KYMR stock, click here.

More about Kymera Therapeutics

Kymera Therapeutics is a leader in the field of Targeted Protein Degradation (TPD), focusing on the development of oral degraders for traditionally undrugged targets in highly validated pathways. The company aims to revolutionize immunology treatment with biologics-like oral therapies, expanding access to millions of patients globally.

Average Trading Volume: 717,224

Technical Sentiment Signal: Sell

Current Market Cap: $1.93B

For detailed information about KYMR stock, go to TipRanks’ Stock Analysis page.